News and Trends 8 Mar 2023 Affibody and Chiesi Group to develop treatments for respiratory diseases …commercial milestone payments up to $637 million plus mid-single to low double-digit royalties on sales. About Affibody molecules Affibody molecules are a novel class of antibody mimetics with characteristics surpassing… March 8, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 15 May 2018 Here Are 10 of the Hottest Biotech Hubs in Europe …Planegg. Right there is one of Europe’s largest biotechs: MorphoSys, a billion-euro biotech that develops antibody therapies. The city is also home to Medigene, which develops T cell receptor technology… May 15, 2018 - 10 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 1 Nov 2022 Human Immunology Biosciences launches with $120M …enhancements that come with our approach.” Clinical-stage assets HI-Bio’s clinical-stage assets include felzartamab, an anti-CD38 antibody, and HIB210, an anti-C5aR1 antibody. Felzartamab targets a protein expressed on the surface of… November 1, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 28 Feb 2023 10 biotech companies making a difference in rare diseases …Founded: 2019 Alchemab Therapeutics is a biotechnology company working on harnessing the power of the immune system to create the next generation of antibody therapeutics for hard-to-treat diseases that do… February 28, 2023 - 11 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 6 Mar 2023 The biggest private biotech investments in February 2023 …will be used to finance an ongoing phase 1/2 trial of a bispecific antibody treatment for the rare bleeding condition Glanzmann thrombasthenia in addition to the launch of a phase… March 6, 2023 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 16 Nov 2020 Innate Immunity in Cancer Gains Recognition with Affimed’s €1.8B Deal …deal’s terms, Affimed will receive €51M upfront to license to Roivant a preclinical-stage antibody drug for several undisclosed types of cancer. Roivant will handle the program once Affimed completes preclinical… November 16, 2020 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 1 Feb 2022 Ethris Raises €23M to Make Inhaled Respiratory Therapies from mRNA …Series B round to fund the development of its lead candidate mRNA therapies — one for respiratory viral infections and the other for the genetic lung condition primary ciliary dyskinesia…. February 1, 2022 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
In Depth 26 May 2023 Could new Lyme disease tests help to prevent chronic infection? …order to create a better Lyme disease test. Dr Abdo Alnabulsi, chief executive officer (CEO) of EpitogenX, stated: “We are working on a serology based antibody test for the detection… May 26, 2023 - 10 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 10 Dec 2025 Promising cure for COPD: Is a breakthrough treatment within reach? …third new COPD therapy to gain approval in the U.S. in less than a year. Nucala is a monoclonal antibody that targets and binds to interleukin-5 (IL-5), a key messenger… December 10, 2025 - 12 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 21 Feb 2018 FDA Approves AstraZeneca’s Lung Cancer Treatment after Rejecting Merck and Pfizer’s …type of monoclonal antibody known as a checkpoint inhibitor that targets the immune regulatory molecule PD-L1. The FDA approval for Imfinzi is the first authorization of a treatment for lung… February 21, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jun 2017 BioNTech Publishes First Data on mRNA-Encoded Cancer Antibodies BioNTech has reported a new technology that could overcome some of the most challenging issues of antibody production by encoding them into mRNA drugs. BioNTech, one of the most advanced… June 12, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 8 Oct 2019 Biotech Hubs: A Tale of Two Cities …founded the online antibody provider Abcam in 1998. Under his leadership, the company grew to be worth over €2B today. Having met with success, Milner became an angel investor in… October 8, 2019 - 6 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email